Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arcturus Therapeutics (ARCT)
NASDAQ:ARCT
Holding ARCT?
Track your performance easily
ARCT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$17.26 - $45.00
Previous Close$19.63
Volume386.63K
Average Volume (3M)352.08K
Market Cap
$506.77M
Enterprise Value$295.58M
Total Cash (Recent Filing)$237.18M
Total Debt (Recent Filing)$25.99M
Price to Earnings (P/E)―
Beta2.39
Next Earnings
Mar 03, 2025EPS Estimate
-$0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.21
Shares Outstanding27,042,246
10 Day Avg. Volume350,809
30 Day Avg. Volume352,082
Standard Deviation0.32
R-Squared0.18
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)2.05
Price to Sales (P/S)3.45
Price to Cash Flow (P/CF)-4.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.81
Enterprise Value/Gross Profit1.77
Enterprise Value/Ebitda-5.02
Forecast
1Y Price Target
$64.33Price Target Upside227.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Arcturus Therapeutics News
PremiumCompany Announcements
Arcturus Therapeutics Reports Q3 2024 Financial Results and Milestones
PremiumCompany Announcements
Arcturus Therapeutics Releases Updated Corporate PresentationBulls Say, Bears Say
Bulls Say
Financial MilestoneArcturus announced eligibility for a $25M milestone payment upon the first sale of Kostaive in Japan.
Manufacturing And DemandMeiji will start manufacturing additional doses of COVID vaccine Kostaive in Japan, indicating increased production and potential higher demand.
Product SuperiorityKostaive maintained superior immunogenicity compared to Pfizer's Comirnaty across multiple variants for up to 12 months post-vaccination.
Bears Say
Market ImpactLimited stock impact is expected because the superiority to Comirnaty was anticipated.
Revenue RecognitionRevenue recognition for the vaccine distribution is assumed to not occur until 2025 due to profit-sharing logistics between CSL and Meiji.
Revenue Timing UncertaintyThe timing of revenue recognition is still TBD given the partnership structure: Meiji reports sales to CSL who then determines ARCT's share.
---
Ownership Overview
8.45% Insiders
31.25% Mutual Funds
27.01% Other Institutional Investors
10.13% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARCT FAQ
What was Arcturus Therapeutics’s price range in the past 12 months?
Arcturus Therapeutics lowest stock price was $17.26 and its highest was $45.00 in the past 12 months.
What is Arcturus Therapeutics’s market cap?
Currently, no data Available
When is Arcturus Therapeutics’s upcoming earnings report date?
Arcturus Therapeutics’s upcoming earnings report date is Mar 03, 2025 which is in 114 days.
How were Arcturus Therapeutics’s earnings last quarter?
Arcturus Therapeutics released its earnings results on Nov 07, 2024. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$1.216 by $0.956.
Is Arcturus Therapeutics overvalued?
According to Wall Street analysts Arcturus Therapeutics’s price is currently Undervalued.
Does Arcturus Therapeutics pay dividends?
Arcturus Therapeutics does not currently pay dividends.
What is Arcturus Therapeutics’s EPS estimate?
Arcturus Therapeutics’s EPS estimate is -$0.68.
How many shares outstanding does Arcturus Therapeutics have?
Arcturus Therapeutics has 27,042,246 shares outstanding.
What happened to Arcturus Therapeutics’s price movement after its last earnings report?
Arcturus Therapeutics reported an EPS of -$0.26 in its last earnings report, beating expectations of -$1.216. Following the earnings report the stock price went up 4.696%.
Which hedge fund is a major shareholder of Arcturus Therapeutics?
Among the largest hedge funds holding Arcturus Therapeutics’s share is ARK Investment Management LLC. It holds Arcturus Therapeutics’s shares valued at 48M.
---
Arcturus Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$64.33 (227.80% Upside)
$64.33 (227.80% Upside)
Blogger Sentiment
Bullish
ARCT Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 299.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.15%
12-Months-Change
Fundamentals
Return on Equity
-21.96%
Trailing 12-Months
Asset Growth
-19.01%
Trailing 12-Months
Company Description
Arcturus Therapeutics
Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.
---
ARCT Company Deck
---
ARCT Earnings Call
Q3 2024
0:00 / 0:00
---
ARCT Stock 12 Month Forecast
Average Price Target
$64.33
▲(227.80% Upside)
Technical Analysis
Best Analysts Covering ARCT
1 Year
1 Year Success Rate
2/13 ratings generated profit
1 Year Average Return
-17.97%
reiterated a buy rating 2 days ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 15.38% of your transactions generating a profit, with an average return of -17.97% per trade.
---